Short Interest in Teva Pharmaceutical Industries Limited (NYSE:TEVA) Grows By 41.5%

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) was the recipient of a significant increase in short interest in January. As of January 31st, there was short interest totalling 22,360,000 shares, an increase of 41.5% from the January 15th total of 15,800,000 shares. Based on an average trading volume of 11,370,000 shares, the short-interest ratio is currently 2.0 days.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on TEVA. Piper Sandler boosted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. Barclays dropped their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating on the stock in a report on Thursday, January 30th. UBS Group dropped their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, January 30th. Finally, StockNews.com lowered Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries currently has a consensus rating of "Moderate Buy" and a consensus target price of $23.57.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA traded down $0.15 during trading on Thursday, reaching $17.02. 10,123,166 shares of the company's stock were exchanged, compared to its average volume of 13,156,166. The business has a 50 day moving average price of $19.92 and a 200-day moving average price of $18.48. The stock has a market capitalization of $19.28 billion, a P/E ratio of -11.73, a PEG ratio of 1.34 and a beta of 0.71. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. Teva Pharmaceutical Industries has a fifty-two week low of $12.51 and a fifty-two week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Sell-side analysts forecast that Teva Pharmaceutical Industries will post 2.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Roberto Mignone sold 286,000 shares of the business's stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now directly owns 695,000 shares in the company, valued at $15,296,950. The trade was a 29.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Corporate insiders own 0.55% of the company's stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of institutional investors have recently bought and sold shares of the business. AQR Capital Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the second quarter valued at approximately $262,000. Cetera Investment Advisers grew its position in shares of Teva Pharmaceutical Industries by 83.9% in the second quarter. Cetera Investment Advisers now owns 60,868 shares of the company's stock valued at $989,000 after purchasing an additional 27,765 shares during the last quarter. Creative Planning grew its position in shares of Teva Pharmaceutical Industries by 4.5% in the third quarter. Creative Planning now owns 42,815 shares of the company's stock valued at $772,000 after purchasing an additional 1,863 shares during the last quarter. Claro Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at approximately $52,000. Finally, Blue Trust Inc. grew its position in shares of Teva Pharmaceutical Industries by 40.1% in the third quarter. Blue Trust Inc. now owns 14,619 shares of the company's stock valued at $263,000 after purchasing an additional 4,185 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.